NCT07025512View on ClinicalTrials.gov

177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 3, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2029

Conditions
Metastatic Castration Resistant Prostate CancerCytopeniaAnemiaThrombocytopenia
Interventions
DRUG

177Lu-PSMA-617

Given by IV

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT07025512 - 177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia | Biotech Hunter | Biotech Hunter